Metabolism of tricyclic antidepressants

Cellular and Molecular Neurobiology

Volumn 19, Issue 3, 1999, Pages 373-409

  Rudorfer, Matthew V ^a   Potter, William Z ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressants; Drug drug interactions; Hydroxy metabolites; Metabolism; Pharmacogenetics; Pharmacokinetics; Plasma concentrations; Toxicity; Tricyclic

Indexed keywords

10 HYDROXYNORTRIPTYLINE; ALCOHOL; AMITRIPTYLINE; AMOXAPINE; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CLOMIPRAMINE; CYTOCHROME P450; DEBRISOQUINE; DESIPRAMINE; DEXFENFLURAMINE; DOSULEPIN; DOXEPIN; DRUG METABOLITE; FENFLURAMINE; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; NORTRIPTYLINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; RECEPTOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; BREAST FEEDING; BREAST MILK; CARDIOTOXICITY; DEMETHYLATION; DEPRESSION; DIET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; GLUCURONIDATION; HEART ARRHYTHMIA; HUMAN; HYDROXYLATION; KIDNEY CLEARANCE; LIVER METABOLISM; NONHUMAN; OBSESSION; OXIDATION; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0032912604     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006949816036     Document Type: Article

References (204)

1. Abernethy, D. R. (1997). Grapefruits and drugs: When is statistically significant clinically significant? (Editorial). J. Clin. Invest. 99:2297-2298.
2. Abernethy, D. R., Greenblatt, D. J., and Shader, R. I. (1984). Imipramine disposition in users of oral contraceptive steroids. Clin. Pharmacol. Ther. 35:792-797.
3. Altshuler, L. L., and Hendrick, V. C. (1996). Pregnancy and psychotropic medication: Changes in blood levels. J. Clin. Psychopharmacol. 16:78-80.
4. Alvan, G., Borga, O., Lind, M., Palmer, L., and Siwers, B. (1977). Concentrations of parent drug and major metabolites in plasma. Eur. J. Clin. Pharmacol. 11:219-224.
5. Amitai, Y., Erickson, T., Kennedy, E. J., Leikin, J. B., Hryhorczuk, D. O., Noble, J., Hanashiro, P. K., and Frischer, H. (1993). Tricyclic antidepressants in red cells and plasma: Correlation with impaired intraventricular conduction in acute overdose. Clin. Pharmacol. Ther. 54:219-227.
6. Amsterdam, J. D., Brunswick, D. J., Potter, W. Z., Winokur, A., and Rickels, K. (1985). Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients: Lack of correlation with therapeutic response. Arch. Gen. Psychiatry 42:361-364.
7. Anonymous (1995). Grapefruit juice interactions with drugs. Med. Lett. 37:73-74.
8. Anton, R. F., Jr., and Burch, E. A., Jr. (1990). Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am. J. Psychiatry 147:1203-1208.
9. Asberg, M., Cronholm, B., Sjöqvist, F., and Tuck, D. (1971). Relationship between plasma levels and therapeutic effect of nortriptyline. Br. Med. J. 3:331-334.
10. Baker, B., Dorian, P., Sandor, P., Shapiro, C., Schell, C., Mitchell, J., and Irvine, J. (1997). Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J. Clin. Psychopharmacol. 17:15-21.
11. Balant-Gorgia, A. E., Balant, L. P., Genet, C., Dayer, P., Aeschlimann, J. M., and Garrone, G. (1986). Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur. J. Clin. Pharmacol. 31:449-455.
12. Balant-Gorgia, A. E., Gex-Fabry, M., and Balant, L. P. (1991). Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. 20:447-462.
13. Bendtsen, L., Jensen, R., and Olesen, J. (1996). A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J. Neurol. Neurosurg. Psychiatry 61:285-290.
14. Ben Musa, A., and Smith, C. S. (1979). Neonatal effects of maternal clomipramine therapy. Arch. Dis. Child. 54405.
15. Bergstrom, R. F., Peyton, A. L., and Lemberger, L. (1992). Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51:239-248.
16. Bertilsson, L., and Dahl, M.-L. (1996). Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223.
17. Bertilsson, L., Nordin, C., Otani, K., Resul, B., Scheinin, M., Siwers, B., and Sjöqvist, F. (1986). Disposition of single oral doses of E-10-hydroxynortriptyline in healthly subjects, with some observations on pharmacodynamic effects. Clin. Pharmacol. Ther. 40:261-267.
18. Bertilsson, L., Mellström, B., and Sjöqvist, F. (1979). Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline. Life Sci. 25:1285-1292.
19. Bertilsson, L., Aberg-Wistedt, A., Gustafsson, L. L., and Nordin, C. (1985). Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug Monit. 7:478-480.
20. Bertilsson, L., Dahl-Puustinen, M.-L., and Nordin, C. (1989). E-10-hydroxynortriptyline: Effects and disposition of a potential novel antidepressant. In Dahl, S. G., and Gram, L. F. (eds.), Clinical Pharmacology in Psychiatry, Springer-Verlag, Berlin, pp. 52-59.
21. Bhagwat, S. V., Bhamre, S., Boyd, M. R., and Ravindranath, V. (1996). Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain. Neuropsychopharmacology 15:133-142.
22. Biederman, J., Baldessarini, R. J., Goldblatt, A., Lapey, K. A., Doyle, A., and Hesslein, P. S. (1993). A naturalistic study of 24-hour electrocardiographic recording and echocardiographic findings in children and adolescents treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry 32: 805-813.
23. Bluhm, R. E., Wilkinson, G. R., Shelton, R., and Branch, R. A. (1993). Genetically determined drug-metabolizing activity and desipramine-associated cardiotoxicity: A case report. Clin. Pharmacol. Ther. 53:89-95.
24. Bock, J., Giller, E., Gray, S., and Jatlow, P. (1982). Steady-state plasma concentrations of cis- and trans-10-H amitriptyline metabolites. Clin. Pharmacol. Ther. 31:609-616.
25. Bock, J. L., Nelson, J. C., Gray, S., and Jatlow, P. (1983). Desipramine hydroxylation: Variability and effect of antipsychotic drugs. Clin. Pharmacol. Ther. 33:322-328.
26. Breyer-Pfaff, U., Giedke, H., Gaertner, H. J., and Nill, K. (1989). Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J. Clin. Psychopharmacol. 9:116-121.
27. Breyer-Pfaff, U., Pfandl, B., Nill, K., Nusser, E., Monney, C., Jonzier-Perey, M., Baettig, D., and Baumann, P. (1992). Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin. Pharmacol. Ther. 52:350-358.
28. Breyer-Pfaff, U., Entenmann, A., and Gaertner, H. J. (1995). Secretion of amitriptyline and metabolites into breast milk. Am. J. Psychiatry 152:812-813.
29. Brixen-Rasmussen, L., Halgrener, J., and Jorgensen, A. (1982). Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology 76:94-95.
30. Brosen, K., Gram, L. F., Klysner, R., and Bech, P. (1986). Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur. J. Pharmacol. 30:43-49.
31. Brown, C. S., Wells, B. G., Cold, J. A., Froemming, J. H., Self, T. H., and Jabbour, J. T. (1990). Possible influences of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. J. Clin. Psychopharmacol. 10:359-362.
32. Browne, J. L., Perry, P. J., Taylor, J. W., Sieleni, B. A., and Kronfol, S. (1984). Nortriptyline capacity-limited metabolism: A case report. J. Clin. Psychopharmacol. 4:322-325.
33. Buist, A., and Janson, H. (1995). Effect of exposure to dothiepin and northiaden in breast milk on child development. Br. J. Psychiatry 167:370-373.
34. Caccia, S., and Garattini, S. (1992). Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol. Res. 26:317-329.
35. Callahan, A. M., Fava, M., and Rosenbaum, J. F. (1993). Drug interaction in psychopharmacology. Psychiatr. Clin. North Am. 16:647-671.
36. Calvo, B., García, M. J., Pedraz, J. L., Mariño, E. L., and Domínguez-Gil, A. (1985). Pharmacokinetics of amoxapine and its active metabolites. Int. J. Clin. Pharmacol. Ther. Toxicol. 23:180-185.
37. Cassidy, S. L., and Henry, J. A. (1987). Fatal toxicity of antidepressant drugs in overdose. Br. Med. J. 295:1021-1024.
38. Cooke, R. G., Warsh, J. J., Stancer, H. C., Reed, K. L., and Persad, E. (1984). The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin. Pharmacol. Ther. 36:343-349.
39. Cutler, N. R., Zavadil, A., Linnoila, M., Scheinin, M., Rudorfer, M. V., and Potter, W. Z. (1984). Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: A preliminary report. Biol. Psychiatry 19:549-556.
40. Dahl-Puustinen, M.-L., Perry, T. L., Dumont, E., von Bahr, C., Nordin, C., and Bertilsson, L. (1989a). Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. Clin. Pharmacol. Ther. 45:650-656.
41. Dahl-Puustinen, M.-L., Åberg-Wistedt, A., and Bertilsson, L. (1989b). Glucuronidation of amitriptyline in man in vivo. Toxicology 65:37-39.
42. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J.R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D.W., Steen, V. M., Wolf, C. R., and Zanger, U. M. (1996). Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
43. Dawkins, K., and Potter, W. Z. (1991). Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: Focus on women. Psychopharmacol. Bull. 27:417-426.
44. Dawling, S., Lynn, K., Rosser, R., and Braithwaite, R. (1982). Nortriptyline metabolism in chronic renal failure: Metabolite elimination. Clin. Pharmacol. Ther. 32:322-329.
45. Delgado, P. L., and Gelenberg, A. J. (1997). Decision making in the use of antidepressants, part II: Choosing a medication. Essent. Psychopharmacol. 1:313-330.
46. Dessain, E. C., Schatzberg, A. F., Woods, B. T., and Cole, J. O. (1986). Maprotiline treatment in depression: A perspective on seizures. Arch. Gen. Psychiatry 43:86-90.
47. DeVane, C. L. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55 (Suppl. 12):38-45.
48. DeVane, C. L., and Jusko, W. (1981). Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine. Drug Intell. Clin. Pharm. 15:263-266.
49. DeVane, C. L., Savett, M., and Jusko, W. J. (1981). Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers. Eur. J. Clin. Pharmacol. 19:61-64.
50. Donnelly, M., Zametkin, A. J., Rapoport, J. L., Ismond, D. R., Weingartner, H., Lane, E., Oliver, J., Linnoila, M., and Potter, W. Z. (1986). Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin. Pharmacol. Ther. 39:72-81.
51. Ducharme, M. P., Provenzano, R., Dehoorne-Smith, M., and Edwards, D. J. (1993). Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol. 36:457-459.
52. Edelbroek, P. M., Zitman, F. G., Knoppert-van der Klein, E. A. M., van Putten, P. M., and de Wolff, F. A. (1987). Therapeutic drug monitoring of amitriptyline: Impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women. Clin. Chim. Acta 165:177-187.
53. Edgar, B., Bailey, D., Bergstrand, R., Johnsson, G., and Regårdh, C. G. (1992). Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine - and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42:313-317.
54. Edwards, D. J., Bellevue, F. H., III, and Woster, P. M. (1996). Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24:1287-1290.
55. El-Fakahany, E., and Richelson, E. (1983). Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br. J. Pharmacol. 78:97-102.
56. Fallon, B. A., and Liebowitz, M. R. (1999). Intravenous clomipramine for obsessive compulsive disorder. In Goodman, W. K., Rudorfer, M. V., and Maser, J. D. (eds.), Treatment Challenges in Obsessive-Compulsive Disorder, Lawrence Erlbaum Associates, Mahwah, NJ (in press).
57. Fleischmann, R., Remmer, H., and Starz, U. (1986). Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking. Eur. J. Clin. Pharmacol. 30:475-480.
58. Fogelson, D. L. (1997). Fenfluramine and the cytochrome P450 system. Am. J. Psychiatry 154:436-437.
59. Gelenberg, A. J., Cooper, D. S., Doller, J. C., and Maloof, F. (1979). Galactorrhea and hyperprolactinemia associated with amoxapine therapy: Report of a case. JAMA 242:1900-1901.
60. Geller, B. (1991). Psychopharmacology of children and adolescents: Pharmacokinetics and relationships of plasma/serum levels to response. Psychopharmacol. Bull. 27:401-409.
61. Geller, B., Cooper, T. B., Graham, D. L., Fetner, H. H., Marsteller, F. A., and Wells, J. M. (1992). Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6-to-12-year olds with major depressive disorder. J. Am. Acad. Child. Adolesc. Psychiatry 31:34-44.
62. Gex-Fabry, M., Balant-Gorgia, A. E., Balant, L. P., and Garrone, G. (1990). Clomipramine metabolism: Model-based analysis of variability factors from drug monitoring data. Clin. Pharmacokinet. 19:241-255.
63. Glassman, A. H., Roose, S. P., and Bigger, J. T., Jr. (1993). The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered. JAMA 269:2673-2675.
64. Golden, R. N., Gilmore, J. H., and Carson, S. W. (1991). Antidepressant challenge tests: The interface of pharmacokinetics and pharmacodynamics. Psychopharmacol. Bull. 27:611-617.
65. Golden, R. N., Bebchuk, J. M., and Leatherman, M. E. (1995).Trazodone and other antidepressants. In Schatzberg, A.F., and Nemeroff, C. B. (eds.), The American Psychiatric Press Textbook of Psychopharmacology, American Psychiatric Press, Washington, DC, pp. 195- 213.
66. Gram, L. F., Bjerre, M., Kragh-Sørensen, P., Kvinesdal, B., Molin, J., and Pedersen, O. L. (1983). Imipramine metabolites in blood of patients during therapy and after overdose. Clin. Pharmacol. Ther. 33:335-342.
67. Greenberg, H. E., England, M. J., and Bjornsson, T. D. (1997). Distribution of pharmacokinetic parameter values for various drug classes. Clin. Pharmacol. Ther. 61:220.
68. Greenblatt, D. J., VonMoltke, L. L., and Shader, R. I. (1996). The importance of presystemic extraction in clinical psychopharmacology. J. Clin. Psychopharmacol. 16: 417-419.
69. Hammer, W., and Sjöqvist, F. (1967). Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 6:1895-1903.
70. Harvey, A. T., and Preskorn, S. H. (1996). Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J. Clin. Psychopharmacol. 16:273-285.
71. Hazell, P., O'Connell, D., and Heathcote, D. (1995). Efficacy of tricyclic drugs in treating child and adolescent depression: A meta-analysis. Br. Med. J. 310:897-901.
72. Huang, C. C. (1986). Persistent tardive dyskinesia associated with amoxapine therapy. Am. J. Psychiatry 143:1069-1070.
73. Jandhyala, B. S., Steenberg, M. L., Perel, J. M., Manian, A. A., and Buckley, J. (1977). Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of anesthetized dogs. Eur. J. Pharmacol. 42:403-410.
74. Jarvis, M. R. (1991). Clinical pharmacokinetics of tricyclic antidepressant overdose. Psychopharmacol. Bull. 27:541-550.
75. Javaid, J. I., Perel, J. M., and Davis, J. M. (1979). Inhibition of biogenic amine uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain. Life Sci. 24:21- 28.
76. Jefferson, J. W. (1995). Tamoxifen-associated reduction in tricyclic antidepressant levels in blood. J. Clin. Psychopharmacol. 15:223-224.
77. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.-L., Sjöqvist, F., and Ingelman-Sundberg, M. (1993). Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90:11825-11829.
78. Kantor, S. J. (1989). Transference and the beta adrenergic receptor: A case presentation. Psychiatry 52:107-115.
79. Kemp, J., Ilett, K. F., and Booth, J. (1985). Excretion of doxepin and N-desmethyldoxepin in human milk. Br. J. Clin. Pharmacol. 20:479-484.
80. Ketter, T. A., Flockhart, D. A., Post, R. M., Denicoff, K., Pazzaglia, P. J., Marangell, L. B., George, M. S., and Callahan, A. M. (1995). The emerging role of cytochrome P450 3 A in psychopharmacology. J. Clin. Psychopharmacol. 15:387-398.
81. Kitanaka, I., Ross, R. J., Cutler, N. R., Zavadil, A. P., and Potter, W. Z. (1982). Altered hydroxydesipramine concentrations in elderly depressed patients. Clin. Pharmacol. Ther. 31:51- 55.
82. Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S., Totsuka, S., and Ishizaki, T. (1996). Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J. Clin. Psychopharmacol. 16:286-293.
83. Krähenbühl, S., Smith-Gamble, V., and Hoppel, C. L. (1996). Pharmacokinetic interaction between diltiazem and nortriptyline. Eur. J. Clin. Pharmacol. 49:417-419.
84. Kutcher, S. P., Reid, K., Dubbin, J. D., and Shulman, K. I. (1986a). Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br. J. Psychiatry 148:676-679.
85. Kutcher, S. P., Shulman, K. I., and Reed, K. (1986b). Desipramine plasma concentration and therapeutic response in elderly depressives: A naturalistic pilot study. Can. J. Psychiatry 31:752- 754.
86. Lancaster, S. G., and Gonzalez, J. P. (1989a). Lofepramine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 37:123-140.
87. Lancaster, S. G., and Gonzalez, J. P. (1989b). Dothiepin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 38:123-147.
88. Lane, E. A. (1991). Renal function and the disposition of antidepressants and their metabolites. Psychopharmacol. Bull. 27:533-540.
89. Lieberman, J. A., Cooper, T. B., Suckow, R. F., Steinberg, H., Borenstein, M., Brenner, R., and Kane, J. M. (1985). Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin. Pharmacol. Ther. 37:301-307.
90. Lin, K.-M., and Poland, R. E. (1995). Ethnicity, culture, and psychopharmacology. In Bloom, F. E., and Kupfer, D. J. (eds.), Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, pp. 1907-1917.
91. Linnoila, M., Insel, T., Kilts, C., Potter, W. Z., and Murphy, D. L. (1982). Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin. Pharmacol. Ther. 32:208-211.
92. Litovitz, T. L., and Troutman, W. G. (1983). Amoxapine overdose. JAMA 250:1069-1071.
93. Lydiard, R. B., and Gelenberg, A. J. (1981). Amoxapine: An antidepressant with some neuroleptic properties? Pharmacotherapy 1:163-178.
94. Malmgren, R., Åberg-Wistedt, A., and Bertilsson, L. (1987). Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. Psychopharmacology 92:169-172.
95. Matheson, J., Pande, H., and Alersten, A. R. (1985). Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 2:1124.
96. McCue, R. E., Georgotas, A., Nagachandran, N., Basir, M. A., Go, E. A., Suckow, R. F., and Cooper, T. B. (1989). Plasma levels of nortriptyline and 10-hydroxynortriptyline and treatment-related electrocardiographic changes in the elderly depressed. J. Psychiatr. Res. 23:73-79.
97. Mellström, B., Bertilsson, L., Säwe, J., Schulz, H.-U., and Sjöqvist, F. (1981). E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxlylation. Clin. Pharmacol. Ther. 30:189-193.
98. Mellström, B., Alvan, G., Bertilsson, L., Potter, W. Z., Säwe, J., and Sjöqvist, F. (1982). Nortriptyline formation after single oral and intramuscular doses of amitriptyline. Clin. Pharmacol. Ther. 32:664-667.
99. Mellström, B., Säwe, J., Bertilsson, L., and Sjöqvist, F. (1986). Amitriptyline metabolism: Association with debrisoquine hydroxylation in nonsmokers. Clin. Pharmacol. Ther. 39:369-371.
100. Musa, M. N. (1989). Nonlinear kinetics of trimipramine in depressed patients. J. Clin. Pharmacol. 29:746-747.
101. Neilsen, K. K., and Gram, L. F. (1992). Steady-state plasma levels of clomipramine and its metabolites: Impact of sparteine/debrisoquine oxidation polymorphism. Eur. J. Pharmacol. 43:405-411.
102. Nelson, J. C., Jatlow, P. I., and Bock, J. (1982). Major adverse reactions during desipramine treatment: Relationship to drug plasma concentrations, concomitant antipsychotic treatment and patient characteristics. Arch. Gen. Psychiatry 39:1055-1061.
103. Nelson, J. C., Bock, J. L., and Jatlow, P. (1983). Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin. Pharmacol. Ther. 33:183-189.
104. Nelson, J. C., Atillasoy, E., Mazure, C., and Jatlow, P. I. (1988a). Hydroxydesipramine in the elderly. J. Clin. Psychopharmacol. 8:428-433.
105. Nelson, J. C., Mazure, C., and Jatlow, P. I. (1988b). Antidepressant activity of 2-hydroxydesipramine. Clin. Pharmacol. Ther. 88:283-288.
106. Nelson, J. C., Mazure, C., and Jatlow, P. I. (1989). Clinical implications of the pharmacokinetics of tricyclic antidepressant. In Dahl, S. G., and Gram, L. F. (eds.), Clinical Pharmacology in Psychiatry, Springer-Verlag, Berlin, pp. 219-227.
107. Ng Ying Kin, N. M. K., Klitgaard, N., Nair, N. P. V., Amin, M., Kragh-Sørensen, P., and Schwartz, G. (1996). Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: A multicenter pharmacokinetic and pharmacodynamic study. Neuropsychpharmacology 15:1-6.
108. Nierenberg, A. A., and Cole, J. O. (1991). Antidepressant adverse drug reactions. J. Clin. Psychiatry. 52 (Suppl. 6):40-47.
109. Nilvebrant, L., and Nordin, C. (1991). Affinity of nortriptyline and its E-10-hydroxy metabolite for muscarinic receptors. Pharmacol. Toxicol. 68:64-67.
110. Nordin, C. (1993). CSF/plasma ratio of 10-hydroxynortriptyline is influenced by sex and body height. Psychopharmacology 113:222-224.
111. Nordin, C., and Bertilsson, L. (1995). Active hydroxymetabolites of antidepressants: Emphasis on E-10-hydroxy-nortriptyline. Clin. Pharmacokinet. 28:26-40.
112. Nordin, C., Bertilsson, L., and Siwers, B. (1985a). CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Br. J. Pharmacol. 20:411-413.
113. Nordin, C., Siwers, B., Benitez, J., and Bertilsson, L. (1985b). Plasma concentrations of nortiptyline and its 10-hydroxy metabolite in depressed patients - Relationship to the debrisoquine hydroxylation metabolic ratio. Br. J. Clin. Pharmacol. 19::832-835.
114. Nordin, C., Bertilsson, L., Otani, K., and Widmark, A. (1987a). Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects. Clin. Pharmacol. Ther. 41:97-102.
115. Nordin, C., Bertilsson, L., and Siwers, B. (1987b). Clinical and biochemical effects during treatment with nortriptyline: The role of 10-hydroxynortriptyline. Clin. Pharmacol. Ther. 42:10-19.
116. Nordin, C., Bertilsson, L., Dahl-Puustinen, M.-L., Resul, B., Toresson, G., and Sjöqvist, F. (1991). Treatment of depression with E-10-hydroxynortriptyline - pilot study on biochemical effects and pharmacokinetics. Psychopharmacology 103:287-290.
117. Nunez, R., and Perel, J. M. (1995). Comparative neurotransmitter reuptake and anticholinergic potencies of the 8-hydroxy metabolites of clomipramine. Psychopharmacol. Bull. 31:217-221.
118. Oesterheld, J., and Kallepalli, B. R. (1997). Grapefruit juice and clomipramine: Shifting metabolic ratios. J. Clin. Psychopharmacol. 17:62-63.
119. Perry, P. J., Browne, J. L., Prince, R. A., Alexander, B., and Tsuang, M. T. (1986). Effects of smoking on nortriptyline plasma concentrations in depressed patients. Ther. Drug. Monit. 8:279-284.
120. Pi, E. H., Tran-Johnson, T. K., Walker, N. R., Cooper, T. B., Suckow, R. F., and Gray, G. E. (1989). Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol. Bull. 25:483-487.
121. Pollock, B. G. (1994). Recent developments in drug metabolism of relevance to psychiatrists. Harv. Rev. Psychiatry. 2:204-213.
122. Pollock, B. G. (1997). Gender differences in psychotropic drug metabolism. Psychopharmacol. Bull. 33:235-241.
123. Pollock, B. G., and Perel, J. M. (1989). Hydroxy metabolites of tricyclic antidepressants: Evaluation of relative cardiotoxicity. In Dahl, S. G., and Gram, L. F. (eds.), Clinical Pharmacology in Psychiatry, Springer-Verlag, Berlin, pp. 232-236.
124. Pollock, B. G., Everett, G., and Perel, J. M. (1992a). Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites. Neuropsychopharmacology 6:1-10.
125. Pollock, B. G., Perel, J. M., Altieri, L., Kirshner, M., Yeager, A., and Reynolds, C.F. (1992b). Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 28:163-168.
126. Pollock, B. G., Mulsant, B. H., Nebes, R., Kirshner, M. A., Begley, A. E., and Reynolds, C. F., III, (1997). Serum anticholinergicity in older patients treated with paroxetine or nortriptyline. Psychopharmacol. Bull. 33::479 (abstract).
127. Potter, W. Z., and Calil, H. M. (1981). Metabolites of tricyclic antidepressants - Biological activity and clinical implications. In Usdin, E. (ed.), Clinical Pharmacology in Psychiatry, Elsevier North-Holland, New York, pp. 311-324.
128. Potter, W. Z., and Manji, H. K. (1990). Antidepressants, metabolites, and apparent drug resistance. Clin. Neuropharmacol. 13 (Suppl 1):S45-S53.
129. Potter, W. Z., Calil, H. M., Manian, A., Zavadil, A. P., and Goodwin, F. K. (1979). Hydroxylated metabolites of tricyclic antidepressants. Biol. Psychiatry 14:601-613.
130. Potter, W. Z., Calil, H. M., Zavadil, A. P., Sutfin, T., Jusko, W. J., and Rapoport, J. (1980). Steadystate concentrations of hydroxylated metabolites of tricyclic antidepressants in patients: Relationship to clinical effect. Psychopharmacol. Bull. 16:32-34.
131. Potter, W. Z., Calil, H. M., Sutfin, T., Zavadil, A. P., Jusko, W. J., and Rapoport, J., and Goodwin, F. K. (1982). Active metabolites of imipramine and desipramine in man. Clin. Pharmacol. Ther. 31:393-401.
132. Potter, W. Z., Lane, E. A., and Rudorfer, M. V. (1983). Hydroxy metabolite concentrations: Role of renal clearance. In Gram, L. F., Usdin, E., Dahl, S. G., Kragh-Sørensen, P., Sjöqvist, F., and Morselli, P. L. (eds.), Clinical Pharmacology in Psychiatry. Bridging the Experimental-Therapeutic Gap, Macmillan Press, London, pp. 203-216.
133. Potter, W. Z., Rudorfer, M. V., and Lane, E. A. (1984). Active metabolites of antidepressants: Pharmacodynamics and relevant pharmacokinetics. In Usdin, E., Bertilsson, L., and Sjögvist, F. (eds.), Frontiers in Biochemical and Pharmacological Research in Depression, Raven Press, New York, pp. 373-390.
134. Potter, W. Z., Scheinin, M., Golden, R. N., Rudorfer, M. V., Cowdry, R. W., Calil, H. M., Ross, R. J., and Linnoila, M. (1985). Selective antidepressants and cerebrospinal fluid: Lack of specificity on norepinephrine and serotonin metabolites. Arch, Gen. Psychiatry 42:1171-1177.
135. Potter, W. Z., Rudorfer, M. V., and Linnoila, M. (1988). New clinical studies support a role of norepinephrine in antidepressant action. In Barchas, J. D., and Bunney, W. E., Jr. (eds.), Perspectives in Psychopharmacology: A Collection of Papers in Honor of Earl Usdin. Alan R. Liss, New York, pp. 495-513.
136. Potter, W. Z., Rudorfer, M. V., and Manji, H. K. (1991). The pharmacologic treatment of depression. N. Engl. J. Med. 325:633-642.
137. Potter, W. Z., Manji, H. K., and Rudorfer, M. V. (1998). Tricyclics and tetracyclics. In Schatzberg, A. F., and Nemeroff, C. B. (eds.), The American Psychiatric Press Textbook of Psychopharmacology, American Psychiatric Press, Washington, DC, pp. 191-218.
138. Preskorn, S. H. (1993). Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J. Clin. Psychiatry 54 (Suppl 9):14-34.
139. Preskorn, S. H. (1996). Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors, Professional Communications, Caddo, OK.
140. Preskorn, S. H., and Fast, G. A. (1991). Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J. Clin. Psychiatry 52 (Suppl 6):23-33.
141. Preskorn, S., and Irwin, H. (1982). Toxicity of tricyclic antidepressants - Kinetics, mechanism, intervention: A review. J. Clin. Psychiatry 43:151-156.
142. Preskorn, S. H., Bupp, S. J., Weller, E. B., and Weller, R. A. (1989). Plasma levels of imipramine and metabolites in 68 hospitalized children. J. Am. Acad. Child Adolesc. Psychiatry 28:373-375.
143. Preskorn, S. H., Alderman, J., Chung, M., Harrison, W., Messig, M., and Harris, S. (1994). Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. 14:90-98.
144. Prince, J., and Wilens, T. E. (1996). Naturalistic study of the coadministration of psychostimulants and desipramine: Effects on serum desipramine levels. Child Adolesc. Psychopharmacol. News 1(2):7.
145. Richelson, E., and Nelson, A. L. (1984). Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Toxicol. Methods 230:94-102.
146. Robinson, D. S., Cooper, T. B., Howard, D., Corcella, J., and Albright, D. (1985). Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J. Clin. Psychopharmacol. 5:83-88.
147. Rudorfer, M. V. (1993a). Challenges in medication clinical trials. Psychopharmacol. Bull. 29:35-44.
148. Rudorfer, M. V. (1993b). Pharmacokinetics of psychotropic drugs in special populations. J. Clin. Psychiatry 54 (Suppl 9):50-54.
149. Rudorfer, M. V., and Potter, W. Z. (1989). Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs 37:713-738.
150. Rudorfer, M. V., and Potter, W. Z. (1997). The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 7:273-312.
151. Rudorfer, M. V., and Young, R. C. (1980a). Desipramine: Cardiovascular effects and plasma levels. Am. J. Psychiatry 137:984-986.
152. Rudorfer, M. V., and Young, R. C. (1980b). Anticholinergic effects and plasma desipramine levels. Clin. Pharmacol. Ther. 28:703-706.
153. Rudorfer, M. V., and Potter, W. Z. (1987). Pharmacokinetics of antidepressants. In Meltzer, H.Y. (ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 1353-1363.
154. Rudorfer, M. V., Golden, R. N., and Potter, W. Z. (1984a). Second-generation antidepressants. Psychiatr. Clin. North Am. 7:519-534.
155. Rudorfer, M. V., Lane, E. A., Chang, W.-H., Zhang, M., and Potter, W. Z. (1984b). Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol. 17:433-440.
156. Rudorfer, M. V., Linnoila, M., and Potter, W. Z. (1987). Accidental antidepressants: Search for specific action. In Dahl, S. G., Gram, L. F., Paul, S. M., and Potter, W. Z. (eds.), Clinical Pharmacology in Psychiatry. IV. Selectivity in Psychotropic Drug Action - Promises or Problems? Springer-Verlag, Heidelberg, pp. 157-166.
157. Rudorfer, M. V., Manji, H. K., and Potter, W. Z. (1994). Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf. 10:18-46.
158. Schimmell, M. S., Katz, E. Z., Shaag, Y., Pastuszak, A., and Koren, G. (1991). Toxic neonatal effects following maternal clomipramine therapy. Clin. Toxicol. 29:479-484.
159. Schneider, L. S., Cooper, T. B., Severson, J. A., Zemplenyi, T., and Sloane, R.B . (1988). Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J. Clin. Psychopharmacol. 8:402-408.
160. Schneider, L. S., Cooper, T. B., Suckow, R. F., Lyness, S. A., Haugen, C, Palmer, R., and Sloane, R. B. (1990). Relationship of hydroxynortriptyline to nortriptyline concentration and creatinine clearance in depressed elderly outpatients. J. Clin. Psychopharmacol. 10:333-337.
161. Shader, R. I., and Greenblatt, D. J. (1997). Fruit juices and pharmacology (Editorial). J. Clin. Psychopharmacol. 17:245-246.
162. Shen, W. W. (1995). Cytochrome P450 monooxygenases and interactions of psychotropic drugs: A five-year update. Int. J. Psychiatry Med. 25:271-284.
163. Shen, W. W. (1997). The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition. Biol. Psychiatry 41:814-826.
164. Shen, W. W., and Lin, K.-M. (1991). Cytochrome P450 monooxygenases and interactions of psychotropic drugs. Int. J. Psychiatry Med. 21:47-56.
165. Shimoda, K., Noguchi, T., Morita, S., Ozeki, Y., Shibasaki, M., Someya, T., and Takahashi, S. (1995a). Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychi-atric population. J. Clin. Psychopharmacol. 15:175-181.
166. Shimoda, K., Noguchi, T., Ozeki, Y., Morita, S., Shibasaki, M., and Someya, T., Takahashi, S. (1995b). Metabolism of clomipramine in a Japanese psychiatric population: Hydroxylation, desmethylation, and glucuronidation. Neurospychopharmacology 12:323-333.
167. Shoaf, S. E., and Linnoila, M. (1991). Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacol. Bull. 27:577-594.
168. Sjöqvist, F. (1989). Pharmacogenetics of antidepressants. In Dahl, S. G., and Gram, L. F. (eds.), Clinical Pharmacology in Psychiatry, Springer-Verlag, Berlin, 1989, pp. 181-191.
169. Skjelbo, E., Brosen, K., Hallas, J., and Gram, L. F. (1991). The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49:18-23.
170. Snyder, S. H., and Yamamura, H. I. (1977). Antidepressants and the muscarinic acetylcholine receptor. Arch. Gen .Psychiatry 34:236-239.
171. Soons, P. A., Vogels, B. A. P. M., Roosemalen, M. C. M., Schoemaker, H. C., Uchida, E., Edgar, B., Lundahl, J., Cohen, A. F., and Breimer, D. D. (1991). Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin. Pharmacol. Ther. 50:394-403.
172. Spence, D. J. (1997). Drug interactions with grapefruit: Whose responsibility is it to warn the public? (Editorial). Clin. Pharmacol. Ther. 61:395-400.
173. Spigset, O., Carleborg, L., Hedenmalm, K., and Dahlqvist, R. (1995). Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58:399-403.
174. Spina, E., and Perucca, E. (1994). Newer and older antidepressants: A comparative review of drug interactions. CNS Drugs 2:479-497.
175. Spina, E., Pollicino, A. M., Avenoso, A., Campo, G. M., Perucca, E., and Caputi, A. P. (1993a). Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. 15:243-246.
176. Spina, E., Pollicino, A. M., Avenoso, A., Campo, G. M., and Caputi, A. P. (1993b). Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int. J. Clin. Pharmacol. Res. 13:167-171.
177. Stewart, D. E. (1992). High-fiber diet and serum tricyclic antidepressant levels. J. Clin. Psychopharmacol. 12:438-440.
178. Sutfin, T. A., DeVane, L. C., and Jusko, W. J. (1984). The analysis and disposition of imipramine and its metabolites in man. Psychopharmacology 82:310-317.
179. Sutfin, T., Perini, G., Molnar, G., and Jusko, W. J. (1988). Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J. Clin. Psychopharmacol. 8:48-53.
180. Taylor, N. E., and Schwartz, H. I. (1988). Neuroleptic malignant syndrome following amoxapine overdose. J. Nerv. Ment. Dis. 176:249-251.
181. Träskman, L., Åsberg, M., Bertilsson, L., Cronholm, B., Mellström, B., Neckers, L. M., Sjöqvist, F., Thoren, P., and Tybring, G. (1979). Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression. Clin. Pharmacol. Ther. 26:600-610.
182. Vitiello, B., and Jensen, P. S. (1995). Developmental perspectives in pediatric psychopharmacology. Psychopharmacol. Bull. 31:75-81.
183. Wägner, A., Ekqvist, B., Bertilsson, L., and Sjöqvist, F. (1984). Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors. Life Sci. 35:1379-1383.
184. Watkins, P. B. (1990). Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin. Liver Dis. 10:235-250.
185. Wilens, T. E., Biederman, J., Baldessarini, R. J., and Puopolo, P. R. (1992). Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J. Am. Acad. Child Adolesc. Psychiatry 31:691-698.
186. Wilens, T. E., Biederman, J., Baldessarini, R. J., Puopolo, P. R., and Flood, J. G. (1993). Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry 32:798-804.
187. Wilens, T. E., Biederman, J., and Spencer, T. J. (1997). Case study: Adverse effects of smoking marijuana while receiving tricyclic antidepressants. J. Am. Acad. Child Adolesc. Psychiatry 36:45- 48.
188. Wilkerson, R. D. (1978). Antiarrhythmic effects of tricyclic antidepressant drugs in ouabain-induced arrhythmias in the dog. J. Pharmacol. Exp. Ther. 206:666-674.
189. Wisner, K. L., and Perel, J. M. (1991). Serum nortriptyline levels in nursing mothers and their infants. Am. J. Psychiatry 148:1234-1236.
190. Wisner, K. L., Perel, J. M., and Wheeler, S. B. (1993). Tricyclic dose requirements across pregnancy. Am. J. Psychiatry. 150:1541-1542.
191. Wisner, K. L., Perel, J. M., and Foglia, J. P. (1995). Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J. Clin. Psychiatry 56:17-20.
192. Wisner, K. L., Perel, J. M., Findling, R. L., and Hinnes, R. L. (1997). Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. Psychopharmacol. Bull. 33:249- 251.
193. Wong, S. L., Cavanaugh, J., Shi, H., Awni, W. M., and Granneman, R. (1996). Effects of divalproes sodium on amitriptyline and nortriptyline pharmacokinetics. Clin. Pharmacol. Ther. 60:48-53.
194. Yonkers, K. A., Kando, J. C., Cole, J. O., and Blumentahl, S. (1992). Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149:587- 595.
195. Young, R. C. (1991). Hydroxylated metabolites of antidepressants. Psychopharmacol. Bull. 27:521-552.
196. Young, R. C., Alexopoulos, G. S., Shamoian, C. A., Dhar, A. K., and Kutt, H. (1984a). Heart failure associated with high plasma 10-hydroxynortriptyline levels. Am. J. Psychiatry 141:432-433.
197. Young, R. C., Alexopoulos, G. S., and Shamoian, C. A. (1984b). Plasma 10-hydroxynortriptyline in elderly depressed patients. Clin. Pharmacol. Ther. 35:540-544.
198. Young, R. C., Alexopoulos, G. S., Kent, E., Shamoian, C. A., Dhar, A. K., and Kutt, H. (1985). Plasma 10-hydroxynortriptyline and ECG changes in elderly depressed patients. Am. J. Psychiatry 142:866-868.
199. Young, R. C., Alexopoulos, G. S., Dhar, A. K., and Kutt, H. (1987). 10-hydroxynortriptyline and renal function in elderly depressives. Biol. Psychiatry 22:1283-1287.
200. Young, R. C., Alexopoulos, G. S., Shindledecker, R., Dhar, A. K., and Kutt, H. (1988a). Plasma 10-hydroxynortriptyline and therapeutic response in geriatric depression. Neuropsychopharmacology 1:213-215.
201. Young, R. C., Dhar, A. K., Kutt, H., Alexopoulos, G. S., and Shamoian, C. A. (1988b). Isomers of 10-hydroxynortriptyline in geriatric depression. Ther. Drug Monit. 10:164-167.
202. Ziegler, V. E., and Biggs, J. T. (1977). Tricyclic plasma levels: Effect of age, race, sex, and smoking. JAMA 238:2167-2169.
203. Ziegler, V. E., Fuller, T. A., and Biggs, J. T. (1976). Nortriptyline and 10-hydroxynortriptyline plasma concentrations. J. Pharm. Pharmacol. 28:849-850.
204. Ziegler, V. E., Biggs, J. T., Wylie, L. T., Coryell, W. H., Hanifl, K. M., Hawf, D. J, and Rosen, S. H. (1978). Protriptyline kinetics. Clin. Pharmacol. Ther. 23:580-584.